•••
I am writing in response to the recent article on United Therapeutics’ plan to invest $100 million in a pig-to-human organ research center (”Pig-to-human organ center proposed,” Aug. 15). While the organ shortage crisis demands substantial innovation, we must critically evaluate the feasibility of xenotransplantation.
For decades, xenotransplantation has been pushed as an innovative solution, but its track record necessitates more scrutiny. Despite efforts to genetically modify pig organs to reduce rejection, success rates in recent clinical use have been disheartening, with patient recipients surviving no longer than two months.
The potential risks of transmitting pig-borne viruses and pathogens to recipients — and the broader community — also remain concerning. Pig organ producers tout pathogen-free environments and extensive screening protocols. Nevertheless, the first pig heart transplanted to a patient was infected with pig cytomegalovirus, a virus shown to be detrimental to transplant outcomes. Even with more rigorous protocols, we can only screen for what we know. These risks may not become fully apparent until widespread use, making timely intervention difficult.
The time to intervene is now. We must explore other paths out of the organ shortage. Strategies such as improving organ donation systems, bolstering chronic disease prevention and advancing existing technologies like organ preservation and tissue bioprinting present promising and realistic solutions.
Biotech companies want you to believe there is a silver bullet (their bottom line depends on it), but getting the organ waitlist to zero will require a comprehensive strategy. Let’s pursue the safer, more reliable human-centered alternatives to xenotransplantation that avoid its definite harms and risks.
Catharine E. Krebs, Harpers Ferry, W.Va.